Clinical outcomes of a new extended-vision intraocular lens in the United Kingdom

Session Details

Session Title: Advanced Optic IOLs

Session Date/Time: Tuesday 17/09/2019 | 08:30-10:30

Paper Time: 08:48

Venue: Free Paper Forum: Podium 1

First Author: : A.Mearza UK

Co Author(s): :    S. Bhermi   N. Patton   H. Kasaby                       

Abstract Details

Purpose:

To evaluate the visual outcomes of subjects implanted with a non-diffractive extended vision intraocular lens (Alcon DFT015) at four sites in the U.K. and compare with the overall study results.

Setting:

Multicenter

Methods:

Four surgeons in the U.K. bilaterally implanted 28 subjects with DFT015 and 21 with the monofocal control (SN60WF) as part of a multicountry, prospective, randomized, subject and assessor masked trial that in total included bilateral implant of 154 subjects with DFT015 and 119 with SN60WF. At 6 months after the second eye implant, the binocular defocus curve, binocular uncorrected visual acuities (UVAs) at distance (UDVA, 4 m), intermediate (UIVA, 66 cm) and near (UNVA, 40 cm), and visual disturbances of haloes, glare and starbursts (QoV, McAlinden) were assessed.

Results:

DFT015 provided 20/20 binocular UDVA; and >half a line improvement in UIVA and > 1 line improvement in UNVA compared to SN60WF. Binocular UVAs for DFT015 at the UK sites were within two letters of the overall. Binocular defocus curves overall and in the UK demonstrated >0.5 D extended range of vision over SN60WF at 0.2 logMAR. In DFT015 and SN60WF groups respectively, 73% and 58% or more subjects were not at all bothered by halos, starbursts and glare (67% and 43% respectively in the UK).

Conclusions:

Consistent with overall results from this multinational study, results in the UK demonstrated that bilateral implantation of this non-diffractive extended vision IOL provided subjects with an extended range of vision from distance to near, while maintaining a monofocal-like visual disturbance profile.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented